News

Optinose CEO and other top executives exit after company's acquisition by Paratek
The deal has a value of up to $330 million, with the final price tied to future sales of Optinose's flagship product.
Le Lézard2d
CureDuchenne Ventures Invests in Entos Pharmaceuticals for Development of a Redosable, Full-Length Dystrophin Gene Therapy
CureDuchenne Ventures announced an initial $1M investment in Entos Pharmaceuticals Inc (Entos), a biotech company that develops genetic medicines utilizing its non-viral, redosable Fusogenix PLV ...